ArticleBioactive materials2026
A composite hydrogel enables the spatiotemporal delivery of distinct cytokines to drive the native vascularized bone regeneration.
Article in Bioactive materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in GelMA Hydrogel-Enabled Angiogenic-Osteogenic Coupling: From Structural Programming to Exogenous Cue Synergy.Journal of functional biomaterials · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone defect represents one of the most prevalent clinical conditions in orthopedics diseases, and the key to successful therapeutic outcomes lies in achieving early vascularization coupled with late-phase osteogenic differentiation. Growth factor delivery is among the most widely adopted strategies for bone tissue regeneration. However, achieving the spatiotemporal coupled regulation of vascularized bone regeneration remains a major challenge. Proprotein convertase subtilisin/kexin type 9 (PCSK9) exerts a pivotal role in bone metabolism. Our preliminary findings demonstrated that PCSK9 expression is upregulated during bone regeneration, while the supplementation of exogenous PCSK9 can enhance the osteogenic differentiation of bone marrow mesenchymal stem cells (BMMSC). Based on these findings, we fabricated a composite hydrogel by adsorbing PCSK9 onto vascular-derived extracellular matrix (ECM) and incorporating vascular endothelial growth factor (VEGF) into gelatin methacryloyl (GelMA). Taking advantage of the distinct sustained-release profiles of these biomaterials, this hydrogel system was engineered to recapitulate the natural bone defect healing process, thereby enabling the coupled regulation of accelerated early vascularization and enhanced late-phase osteogenic differentiation. Both in vitro and in vivo experimental results confirmed that the constructed composite hydrogel can further potentiate the therapeutic efficacy of PCSK9 and achieve efficient vascularized bone regeneration. Mechanistically, our findings revealed that PCSK9 promotes the osteogenic differentiation of BMMSC via activation of the ERK signaling pathway. Collectively, the PCSK9- and VEGF-loaded composite hydrogel exhibits promising pro-angiogenic and pro-osteogenic coupling capabilities for bone regeneration, which provides novel therapeutic targets and innovative strategies for the clinical management of bone defects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.